Please be aware that this site uses cookies
More information
News and Events

Tumour Suppressor Role for Dok2 and Dok6 Genes in Human Breast Cancer

In an article in the current issue of The World Journal of Clinical Oncology, the research team at The London Breast Institute led by Prof. Kefah Mokbel have reported a tumour suppressor role for Dok2 and Dok6 genes in human breast cancer http://www.wjgnet.com/2218-4333/pdf/v5/i2/156.pdf. In an editorial in the same issue of the journal, Prof. Mokbel outlined the recent advances in skin-sparing mastectomy (SSM) and immediate reconstruction: http://www.wjgnet.com/2218-4333/pdf/v5/i2/33.pdf. Prof. Mokbel commented in the editorial: Due to the fact that it is not feasible to conduct randomised controlled trials, there is a continuous need to publish updated meta-analyses from time to time, in order to ensure that the oncological safety of SSM remains intact. Such meta-analyses should assess the risk of bias (selection bias, detection bias, attrition and reporting bias) and study heterogeneity. Overall survival and disease-free survival (DFS) should be the primary end points of the meta-analysis while the secondary endpoints should include surgical complications and quality of life. This topic was also addressed in a recent review by the Breast Surgery Team at the LBI published in Journal of Cancer Therapy: http://file.scirp.org/Html/10-2300387_27366.htm